OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0

作者：

Lynch, T. J., Jr. ^{[1
]}

Neal, J. ^{[2
]}

Bondarenko, I. ^{[3
]}

Luft, A. ^{[4
]}

Serwatowski, P. ^{[5
]}

Barlesi, F. ^{[9
]}

Chacko, R. ^{[10
]}

Sebastian, M. ^{[6
]}

Cuillerot, J. ^{[7
]}

Reck, M. ^{[8
]}

机构：

[1] Yale Univ, Ctr Canc, New Haven, CT USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[3] Dnipropetrovsk Municipal Clin Hosp 4, Dept Oncol Radiodiagnosis & Radioth, Dnepropetrovsk, Ukraine

[4] Leningrad Reg Clin Hosp, State Inst, St Petersburg, Russia

[5] Oddzial Chemioterapii, Szczecin, Poland

[6] Johannes Gutenberg Univ Mainz, Mainz, Germany

[7] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA

[8] Hosp Grosshansdorf, Grosshansdorf, Germany

[9] Univ Mediterranee Assistance Publ Hapitaux Marsei, Marseille, France

[10] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：126 / 126

页数：1